Journal of clinical cardiology and cardiovascular therapy最新文献_第7页

The Role of Cardiac Biomarkers in Predicting of Mortality in Diabetic Patients 心脏生物标志物在预测糖尿病患者死亡率中的作用

Journal of clinical cardiology and cardiovascular therapy Pub Date : 2015-10-10 DOI: 10.17554/J.ISSN.2309-6861.2015.02.94

A. Berezin

引用次数: 8

2015 Guidelines on Treatment of Hypertension in Patients With Coronary Artery Disease 2015冠状动脉病患者高血压治疗指南

Journal of clinical cardiology and cardiovascular therapy Pub Date : 2015-10-10 DOI: 10.17554/j.issn.2309-6861.2015.02.92

W. Aronow

{"title":"2015 Guidelines on Treatment of Hypertension in Patients With Coronary Artery Disease","authors":"W. Aronow","doi":"10.17554/j.issn.2309-6861.2015.02.92","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.92","url":null,"abstract":"Patients with coronary artery disease should have intensive treatment of modifiable coronary risk factors. Dietary sodium should be decreased. Hypertension should be treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Long-acting nitrates are effective antianginal and antiischemic medications. Calcium channel blockers may be added if angina pectoris persists despite beta blockers and long-acting nitrates. The American Heart Association/American Society of Cardiology 2015 guidelines recommend a target blood pressure below 140/90 mm Hg in patients with coronary artery disease and with an acute coronary syndrome if they are aged 80 years and younger but below 150 mm Hg if they are ≥80 years of age. Octogenarians should be checked for orthostatic changes with standing, and a a systolic blood pressure below 130 mm Hg and a diastolic blood pressure below 65 mm Hg must be avoided. Caution is advised in lowering the diastolic blood pressure below 60 mm Hg in diabetics or in patients older than 60 years of age. In addition to the beta blockers carvedilol, metoprolol CR/XL, and bisoprolol, patients with hypertension and heart failure should be treated with diuretics and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and patients with persistent severe symptoms with aldosterone antagonists if not contraindicated.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"3 1","pages":"418-421"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79344050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bedside Echocardiography In Patients With Hip Fracture 髋部骨折患者的床边超声心动图

Journal of clinical cardiology and cardiovascular therapy Pub Date : 2015-10-10 DOI: 10.17554/j.issn.2309-6861.2015.02.88

C. Rostagno

引用次数: 0

New Clinical Trials With Evolocumab and Alirocumab on Cardiovascular Outcomes, in Patients With High Rsk of Acute Coronary Syndromes Evolocumab和Alirocumab对急性冠状动脉综合征高危患者心血管结局的新临床试验

Journal of clinical cardiology and cardiovascular therapy Pub Date : 2015-10-10 DOI: 10.17554/j.issn.2309-6861.2015.02.93

R. Singh, K. Hristova, J. Fedacko, G. Elkilany, N. Verma

引用次数: 0

Cardiovascular benefits and risk profiles of oral anti-diabetic agents: current evidence and ongoing trials 口服抗糖尿病药物的心血管益处和风险概况:现有证据和正在进行的试验

Journal of clinical cardiology and cardiovascular therapy Pub Date : 2015-10-10 DOI: 10.17554/j.issn.2309-6861.2015.02.87

Yi-Cheng Chang, Juey-Jen Hwang, Shih-Che Hua

{"title":"Cardiovascular benefits and risk profiles of oral anti-diabetic agents: current evidence and ongoing trials","authors":"Yi-Cheng Chang, Juey-Jen Hwang, Shih-Che Hua","doi":"10.17554/j.issn.2309-6861.2015.02.87","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.87","url":null,"abstract":"Type 2 diabetes increases the risk of developing cardiovascular (CV) morbidity and mortality. Strict glycemic control may produce CV benefit in newly diagnosed or short duration diabetes, but not in longstanding complicated diabetic patients, especially in those with high risk of hypoglycemia. In 2008, the US Food and Drug Administration (FDA) revised regulations for the approval of medications for type 2 diabetes by requiring adequate CV safety evidences. Recently, major concerns have arisen about current oral anti-diabetic agents (OADs). This review will be focused on CV benefits and risk profiles of currently available OADs based on evidences from landmark randomized controlled trials and meta-analyses. Metformin, sulfonylureas (SUs), and alpha-glucosidase inhibitors have limited and/or controversial data on CV safety evaluation. Peroxisome proliferator-activated receptor gamma agonists or thiazolidinediones EDITORIAL Cardiovascular Benefits and Risk Profiles of Oral Anti-Diabetic Agents: Current Evidence and Ongoing Trials Shih-Che Hua, Juey-Jen Hwang, Yi-Cheng Chang 386 Journal of Cardiol Ther 2015 October 2(5): 386-392 ISSN 2309-6861(print), ISSN 2312-122X(online) Online Submissions: http://www.ghrnet.org/index./jct/ doi:10.17554/j.issn.2309-6861.2015.02.87 © 2015 ACT. All rights reserved. Journal of Cardiology and Therapy (TZDs), dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodiumglucose co-transporter type 2 (SGLT2) inhibitors have been more extensively evaluated in well-designed CV outcome trials. A recently published randomized clinical trials demonstrated empagliflozin reduced CV risks and mortality in high CV risks type 2 diabetes patients. Ongoing trials will elucidate the CV safety for TZDs (pioglitazone), DPP-4 inhibitors, and SGLT2 inhibitors compared to SUs or placebo. © 2015 ACT. All rights reserved.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"18 1","pages":"386-392"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82501521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Clinical Outcomes of Pharmaco-invasive ST-elevation Myocardial Infarction Management in a Large Australian Regional Centre 澳大利亚一个大型区域中心药物侵入性st段抬高心肌梗死治疗的临床结果

Journal of clinical cardiology and cardiovascular therapy Pub Date : 2015-10-10 DOI: 10.17554/j.issn.2309-6861.2015.02.79

Bo Xu, V. Nadurata, K. Avery, C. Chilvers, Shelene Laiu

{"title":"Clinical Outcomes of Pharmaco-invasive ST-elevation Myocardial Infarction Management in a Large Australian Regional Centre","authors":"Bo Xu, V. Nadurata, K. Avery, C. Chilvers, Shelene Laiu","doi":"10.17554/j.issn.2309-6861.2015.02.79","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.79","url":null,"abstract":"Background: Primary percutaneous coronary intervention (PCI) is the standard of care for ST-elevation myocardial infarction (STEMI). In rural and remote centres with limited facilities, a pharmaco-invasive approach with thrombolysis followed by transfer of patients to PCI-capable centres remains important. Contemporary Australian data regarding pharmaco-invasive STEMI management are lacking. The primary objective of this study was to examine the clinical outcomes of pharmaco-invasive STEMI management in Bendigo, a large Australian regional centre. Methods: A retrospective analysis was performed for all patients presenting to Bendigo Health with an admission diagnosis of STEMI in the emergency department, between February 2013 and January 2014. During the study period, 68 consecutive patients received an admission diagnosis of STEMI in the emergency department. Of these, 58 patients were actually diagnosed with STEMI due to obstructive coronary artery disease, and received thrombolysis. These patients were divided into two groups: (1) Pharmaco-invasive local (Local) group: thrombolysis with subsequent coronary angiography locally in Bendigo; (2) Pharmaco-invasive transfer (Transfer) group: thrombolysis with immediate transfer for coronary angiography. Door-to-Needle time (DTN), Thrombolysis-to-Angiography time (TTA), transfer cost, and inpatient morbidity and mortality were collected. Results: DTN was more prolonged in the Local group (38 ± 35 minutes versus 25 ± 23 minutes, p=0.135). DTN 24 hours for angiography, and a significantly higher proportion of patients being managed by surgery and medical therapy. In a contemporary regional Australian pharmaco-invasive STEMI cohort, significant opportunities existed to improve patient outcomes.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"45 1","pages":"430-435"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88105099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can Prevention of Low Birth Weight in Newborn may be Associated with Primordial Prevention of Cardiovascular Diseases and Type 2 Diabetes in Adult Life 预防新生儿低出生体重可能与成人心血管疾病和2型糖尿病的初步预防有关吗

Journal of clinical cardiology and cardiovascular therapy Pub Date : 2015-10-10 DOI: 10.17554/j.issn.2309-6861.2015.02.90

R. Singh, B. Saboo, A. Maheshwari, Poonam Singh, N. Verma, S. Singhal, Z. P. Sharma

{"title":"Can Prevention of Low Birth Weight in Newborn may be Associated with Primordial Prevention of Cardiovascular Diseases and Type 2 Diabetes in Adult Life","authors":"R. Singh, B. Saboo, A. Maheshwari, Poonam Singh, N. Verma, S. Singhal, Z. P. Sharma","doi":"10.17554/j.issn.2309-6861.2015.02.90","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.90","url":null,"abstract":"Poor nutrition during pregnancy may be a risk factor for low birth weight and for irreversible health issues including obesity, type 2 diabetes, hypertension and hypercholesterolemia in adult life. Low birth weight has also been related to greater mortality from coronary artery disease(CAD) and type 2 diabetes in adult life. One earlier study from Northern Europe proposed that poor social conditions in childhood may be risk factor for obesity, diabetes and cardiovascular diseases (CVDs) in later life. It is possible that multiple confounders related to energy and micronutrient deficiencies may be interacting in the process of adaptations in critical time periods, during fetal, postnatal and child development. A review of literature on the effects on birth size and length of babies and of multiple micronutrient supplementation during pregnancy in low-income countries indicates that incidence of low birth weight may be decreased by supplementation of about 15 micronutrients. This finding poses the possibility that for prevention of low birth weight, maternal micronutrient supplementation (15-20 nutrients) may be an important strategy. It is proposed that this strategy may lead the prevention of CVDs and type 2 diabetes in adult life. Cohort studies and long term follow up population based trials are needed to confirm this hypothesis.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"53 1","pages":"425-429"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79315289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Electrocardiographic Features in the Diagnosis and Risk Assessment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia 致心律失常性右室心肌病/发育不良的心电图特征诊断和风险评估

Journal of clinical cardiology and cardiovascular therapy Pub Date : 2015-10-10 DOI: 10.17554/j.issn.2309-6861.2015.02.91

S. Peters

引用次数: 0

Giant Left Ventricular Pseudoaneurysm after Acute Myocardial Infarction Secondary to Cocaine Use 可卡因致急性心肌梗死后巨大左心室假性动脉瘤

Journal of clinical cardiology and cardiovascular therapy Pub Date : 2015-08-10 DOI: 10.17554/j.issn.2309-6861.2015.02.84

A. Soeiro, F. Fernandes, Maria Guerreiro, Thiago Marques Mendes, M. Soeiro, T. A. Lea, D. Nakamura, F. Gaiotto, M. Oliveira

引用次数: 0

Obesity Paradox in Asian Population: the Protective Effects of Excessive Body Mass 亚洲人口肥胖悖论:过度体重的保护作用

Journal of clinical cardiology and cardiovascular therapy Pub Date : 2015-08-10 DOI: 10.17554/j.issn.2309-6861.2015.02.85

Yau-Huei Lai, J. Kuo

引用次数: 0